Arbutus Biopharma (ABUS) Change in Acquisitions & Divestments (2015 - 2026)

Arbutus Biopharma has disclosed Change in Acquisitions & Divestments across 10 years of filings, most recently posting $16.0 million for Q1 2026.

• Change in Acquisitions & Divestments for Q1 2026 came in at $16.0 million, down 65.27% year-over-year; the trailing twelve-month figure through Mar 2026 was $125.2 million (down 27.84% YoY), and the FY2025 annual result was $155.3 million, down 5.69% from the prior year.
• Change in Acquisitions & Divestments came in at $16.0 million for Q1 2026 at Arbutus Biopharma, down from $23.8 million in the prior quarter.
• In the past five years, Change in Acquisitions & Divestments ranged from a high of $56.7 million in Q4 2024 to a low of $2.0 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $31.5 million (2023), against an average of $30.8 million.
• Across the five-year window, Change in Acquisitions & Divestments tumbled 90.17% in 2022 and surged 1750.0% in 2023, its largest moves.
• Arbutus Biopharma's Change in Acquisitions & Divestments stood at $26.0 million in 2022, then jumped by 77.86% to $46.2 million in 2023, then gained by 22.58% to $56.7 million in 2024, then tumbled by 57.96% to $23.8 million in 2025, then sank by 32.86% to $16.0 million in 2026.
• The last three Change in Acquisitions & Divestments figures came in at $16.0 million (Q1 2026), $23.8 million (Q4 2025), and $41.3 million (Q3 2025), per Business Quant data.